Amanda Holden-hosted quiz The Celebrity Inner Circle just wrapping up on BBC1. There always seems to be a Strictly alumna or two among the guests and this week, it’s…
The success rate of hormone therapy for breast cancer is among the highest of all treatment options available for hormone receptor–positive (HR+) disease. Hormone therapy—also called endocrine therapy—is one of the most…
We recently published 10 Stocks Beating Wall Street’s Bets. Garrett Motion Inc. (NASDAQ:GTX) is one of the best performers on Friday.
Garrett Motion capped Friday’s trading soaring to a new all-time high as investors continued to digest impressive earnings for the past quarter, alongside a higher growth outlook.
At intra-day trading, the stock soared to a record high of $17.05 before trimming gains to finish the day up by 13.8 percent at $16.99 apiece.
In an updated report on Thursday, Garrett Motion Inc. (NASDAQ:GTX) said it grew its net income by 48 percent to $77 million from $52 million in the same period last year, on the back of a $20 million jump in gross profit, $8 million lower interest cost, and a $2 million increase in non-operating income.
Garrett Motion (GTX) Climbs to Fresh High on Impressive Earnings, Upbeat Outlook
laurel-and-michael-evans-c-KDq7nxVdQ-unsplash
Net sales, on the other hand, rose by 9.2 percent to $902 million from $826 million year-on-year, primarily driven by higher demand in gasoline and diesel, a favorable currency impact, and recoveries on enacted import tariffs.
Following the results, Garrett Motion Inc. (NASDAQ:GTX) raised its full-year net income projection to a range of $265 million to $295 million, versus the $233 million to $278 million previously.
Net sales projection was also upgraded to a range of $3.5 billion to $3.6 billion, versus the $3.4 billion to $3.6 billion prior.
While we acknowledge the potential of GTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
The success rate of hormone therapy for breast cancer is among the highest of all treatment options available for hormone receptor–positive (HR+) disease. Hormone therapy—also called endocrine therapy—is one of the most…